144 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability
8-K
EX-99.1
2u7zje
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
8-K
EX-99.1
9rfr2p8
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.1
4uyg4b646o7id6 8e
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.2
ma1o42qqtz93pu1xm
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
65p0f r6zjscdx2
16 Oct 23
Regulation FD Disclosure
8:05am
424B5
lp5yn jilnm2oits
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
hvx60
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
lj1e scmk38h605
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
PRE 14A
rm1rvw8lgydizrquvd1o
31 Mar 23
Preliminary proxy
4:02pm